Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

The Ukrainian government has instigated rapid cost-cutting measures across the drug retail sector, triggered by reports of ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

For cell and gene therapy, a consistent supply of quality starting material is vital that is maintained throughout the ...

Non-profit organisations provide an alternative to rescue stalled orphan drugs for biotechs struggling against a lethargic ...

Completed biopharma IPOs that raised more than $100 million saw a twofold increase during the year. Biopharmaceutical initial ...

Use of GLP-1RA therapies in CV/CKD disease with T2D will likely rise as physicians view them as addressers of cardiometabolic ...

Based on the Phase II data, Imbria Pharmaceuticals’ inerafaxstat could complement existing treatments rather than replace them.

Shorter trial authorisation timelines for ATMP trials in the US are an advantage for biotechs, say experts. Although the ...

Bioconjugation presents an new frontier for pharmaceutical development, providing an option for improved drug efficacy across ...

MSD has entered an exclusive licence agreement with Hengrui Pharma for the oral small molecule Lp(a) inhibitor, HRS-5346.